Project Grant K01AI200013
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $199K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $110,228 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural and functional mechanisms of antibiotic substrate translocation in bacterial resistance-nodulation-division (RND) family efflux pumps. The research addresses the challenge of intrinsic antibiotic resistance in Pseudomonas aeruginosa, which encodes twelve RND efflux pumps, at least four of...
- The National Institute of Allergy and Infectious Diseases awarded $157,356 to the University of Georgia Research Foundation, Inc. on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct strain-resolved metagenomics analysis of Bifidobacterium infantis colonization in early infancy and its associations with child health outcomes. The research generates shotgun metagenome data from biobanked infant stool samples collected through the ECOMID birth...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on February 5, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct research on substrate selectivity and inhibition mechanisms of the Pseudomonas aeruginosa MexXY efflux system, a resistance-nodulation-division (RND) transporter complex that confers antibiotic resistance by pumping drugs out of bacterial cells. MexXY-OprM is unique among P. aeruginosa...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on October 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on small molecule regulation of an antibiotic resistance efflux pump in Pseudomonas aeruginosa. The research examines the MexXY-OprM efflux pump, the only efflux system in P. aeruginosa capable of exporting aminoglycosides, a clinically relevant antibiotic. The project investigates how the...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $500,500 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunometabolic dysfunction in myeloid-derived suppressor cells (MDSCs) among people living with HIV who are at elevated risk for tuberculosis despite antiretroviral therapy and CD4 reconstitution. The research leverages biobanked cryopreserved peripheral blood mononuclear cell samples available...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $412,749 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into enhancers that facilitate genetic manipulation of specific B-cell subsets. The research identifies cis-regulatory elements (enhancers) that control cell-type and context-specific gene expression in memory B cells and antibody-secreting plasma cells, with the goal of developing precise genetic...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $159,140 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct molecular epidemiology research on New Delhi metallo-B-lactamase-producing Enterobacterales (NDM-E) infections. The research integrates genotype, phenotype, and patient-level outcomes to develop allele-specific therapeutic guidance for NDM-E treatment. Aim 1 defines the genetic epidemiology of...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $2,456,616 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on heteroresistance, an enigmatic form of antibiotic resistance in which bacterial isolates harbor resistant subpopulations that replicate in the presence of antibiotics while susceptible majority populations are killed. The research addresses the urgent challenge of antibiotic resistance, which...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $159,764 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate gastrointestinal immune and microbiome responses to Shigella infection in children. The recipient will characterize mucosal immune markers and microbiome composition associated with susceptibility to Shigella infection in children under five years old living in low- and...